https://www.selleckchem.com/pr....oducts/Staurosporine
Recent case reports have described the efficacy of daratumumab to treat refractory pure red cell aplasia (PRCA) following major ABO mismatched allogeneic hematopoietic stem cell transplantation (HSCT). In this report, we describe the use of daratumumab as a first-line agent for treatment of delayed red blood cell (RBC) engraftment following a major ABO mismatched pediatric HSCT and provide a review of the literature. We report on a 14-year-old with DOCK8 deficiency who underwent a myeloablative, haploidentical bone marrow transpla
Like
Comment
Share
